PMPapon Muangsanit

Papon Muangsanit

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Papon Muangsanit has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Anan Jongkaewwattana

    Virology and Vaccine Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, Thailand

    2 shared publications
  • Benjamas Liwnaree

    Veterinary Health Innovation and Management Research Group, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, Thailand

    2 shared publications
  • Challika Kaewborisuth

    Virology and Vaccine Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani, Thailand

    2 shared publications
  • Eleni Costa

    Department of Pharmacology, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, Bloomsbury, London WC1N 1AX, United Kingdom

    2 shared publications
  • James Benjamin Phillips

    University College London School of Pharmacy

    2 shared publications
  • Jarin Kramyu

    Virology and Vaccine Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, Thailand

    2 shared publications

Latest Publications

  • Open Access

    Development of azithromycin-loaded nanostructured lipid carriers for nebulized delivery in cystic fibrosis-associated Pseudomonas aeruginosa infections

    by Nandar Tint Lwin, Veerakiet Boonkanokwong, Wongsakorn Phongsopitanun, Ungkarn Jarujareet, Papon Muangsanit, Sudartip Areecheewakul, Jittima Chatchawalsaisin, Nattika Nimmano

  • Open Access

    Development and Characterization of Celecoxib-Loaded Soluplus/Zein Composite Nanoparticles Coated with Chitosan for Pulmonary Drug Delivery

    by Khin Cho Nyein, Maxius Gunawan, Papon Muangsanit, Sudartip Areecheewakul, Jittima Chatchawalsaisin, Nattika Nimmano

    Non-small cell lung cancer (NSCLC), the most common subtype of lung cancer, remains a major contributor to cancer-related mortality worldwide. Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, has beenrepurposed as an anticancer agent for NSCLC therapy. In the present study, celecoxib-loaded Soluplus/zein composite nanoparticles coated with chitosan were successfully developed and evaluated as a promising pulmonary drug delivery system for NSCLC. The nanoparticles were prepared using an antisolvent precipitation technique and demonstrated favorable physicochemical properties. The optimized formulation exhibited a particle size of approximately 190 nm with high encapsulation efficiency (85.34%), and high drug-loading capacity (14.21%). The chitosan coating increased the zeta potential to nearly +30.42 mV, yielding enhanced stability and desirable mucoadhesive properties for pulmonary administration. In vitro release studies revealed sustained release under simulated physiological lung conditions, following diffusion- and swelling-controlled release mechanisms. Cytotoxicity evaluation using the MTT assay demonstrated significant anticancer activity against A549 lung cancer cells while maintaining good biocompatibility toward BEAS-2B normal human bronchial epithelial cells. The optimized nanoparticles also showed efficient transport across an air–liquid interface (ALI) airway epithelial barrier, with a Papp value of 4.15 × 10–4 cm·s–1 and 0.38% translocation after 24 h. Furthermore, aerosolized nanoparticles displayed excellent aerodynamic performance, with a fine particle fraction (FPF) of 68.51% and a mass median aerodynamic diameter (MMAD) of 3.93 μm using the Next Generation Impactor (NGI). Overall, these findings highlight the potential of celecoxib-loaded Soluplus/zein nanoparticles coated with chitosan as a promising pulmonary drug delivery system for NSCLC via nebulization.


  • Open Access

    Evaluation of a Cell-Adapted Live Attenuated African Swine Fever Virus Thai-Strain Vaccine Candidate: Highlighting Enhanced Virulence Risk in Co-Infected Pigs

    by Challika Kaewborisuth, Theeradej Thaweerattanasinp, Nanchaya Wanasen, Apidsada Chorpunkul, Payuda Hansoongnern, Nathiphat Tanwattana, Kanjana Srisutthisamphan, Janya Saenboonrueng, Asawin Wanitchang, Suphot Wattanaphansak, et al.

    Background/Objectives: African swine fever (ASF) is a devastating disease affecting the swine industry globally. Development of safe and effective vaccines is an urgent need. This study aimed to evaluate, caASFV001-MA52, a cell-adapted ASFV strain derived from serial passaging in MA-104 cells, as a promising live-attenuated vaccine (LAV) candidate against virulent ASFV infection. Methods: Seven-week-old, crossbred pigs were immunized with caASFV001-MA52 (at a dose of 105 TCID50) and subsequently challenged with a lethal dose of virulent ASFV. Vaccine efficacy was measured through clinical monitoring, immunological and virological analyses, and pathological assessments of tissue protection and viral load reduction. Safety was critically assessed, particularly regarding its profile in animals with concurrent endemic porcine infections, including PCV, PRRSV and S. suis. Results: caASFV001-MA52 exhibits partial protection (70–80%) against the lethal challenge. Vaccinated and challenged survivors exhibited reduced viral loads and significantly alleviated pathological lesions compared to controls. Safety evaluations revealed that the vaccine’s profile is susceptible to concurrent infection. Pigs co-infected with endemic porcine pathogens showed increased virulence and mortality following vaccination. Although vaccination temporarily reactivated latent viral infections (PCV2, PCV3, and PRRSV), most surviving pigs effectively controlled and eliminated these co-infections. Conclusions: The caASFV001-MA52 strain demonstrates promising immunogenicity and protection against lethal challenges, supporting its continued development as an LAV candidate. However, the observed safety concerns regarding concurrent infections emphasize the critical need for veterinary health surveillance during its future practical application.


  • Open Access

    Cytotoxicity and antifungal effects of combined dexamethasone and miconazole on human oral keratinocytes, gingival fibroblasts, and Candida albicans

    by Papon Muangsanit, Supathep Tansirichaiya, Puangwan Lapthanasupkul, Chidchanok Leethanakul, Kununya Pimolbutr, Weerachai Singhatanadgit

    Oral lichen planus (OLP), a prevalent immune-mediated inflammatory condition, requires effective therapies. Topical corticosteroids, such as dexamethasone, are widely used for OLP treatment. However, they can predispose patients to secondary candidiasis, necessitating adjunctive therapy with antifungal agents like miconazole. Little is known about the cellular dynamics and toxicity of the combined use of dexamethasone and miconazole. This study examined the effect of dexamethasone on the antifungal activity of miconazole against Candida albicans and the effect of miconazole on the immunosuppressive activity of dexamethasone on human T cells. The cytotoxicity of dexamethasone alone and dexamethasone combined with miconazole on human oral keratinocytes and gingival fibroblasts was also determined using both in vitro monolayer and Transwell co-culture models. A 5-min incubation thrice daily cell treatment protocol was employed for all assays. Dexamethasone did not affect miconazole’s antifungal efficacy, and a single exposure of miconazole inhibited over 99% of C. albicans growth. In monolayer cultures, 0.05% dexamethasone was non-toxic to keratinocytes and fibroblasts, while miconazole exhibited dose-dependent cytotoxicity at high concentrations. Transwell co-culture models confirmed this dose-dependent cytotoxicity, with higher miconazole concentrations causing increased apoptosis. Dexamethasone significantly reduced T cell viability, activation, and proliferation, unaffected by miconazole co-treatment. In conclusion, when used in combination at optimal concentrations, miconazole’s antifungal activity and dexamethasone’s anti-T-cell proliferation activity are retained without cytotoxicity to human oral cells. Further research is needed to validate these findings and develop evidence-based treatments for oral lichen planus.


  • Regenerative Potential of Neural Stem/Progenitor Cells for Bone Repair

    by Papon Muangsanit, Pinyaphat Yuddnaraveesak, Weerachai Singhatanadgit

    The increasing number of elderly people across the globe has led to a rise in osteoporosis and bone fractures, significantly impacting the quality of life and posing substantial health and economic burdens. Despite the development of tissue-engineered bone constructs and stem cell-based therapies to address these challenges, their efficacy is compromised by inadequate vascularization and innervation during bone repair. Innervation plays a pivotal role in tissue regeneration, including bone repair, and various techniques have been developed to fabricate innervated bone scaffolds for clinical use. Incorporating neural-related cells and delivering neurotrophic factors are emerging strategies to accelerate bone regeneration through innervation. However, research into neurogenic cell sources remains limited. Meanwhile, neural stem/progenitor cells (NSPCs) are emerging as promising cells for treating neurodegenerative disorders and spinal cord injuries due to their multifunctional capacity in promoting angiogenesis, neurogenesis, and immunomodulation, making them promising candidates for achieving innervation in bone substitutes. In this review, we discuss the regenerative potential of NSPCs in tissue regeneration. We propose their feasibility for bone therapy through their secreted exosomes during traumatic brain injury, contributing to the acceleration of bone healing. Additionally, we discuss the essential neurotrophic factors released from NSPCs and their osteogenic properties. This review emphasizes the necessity for further investigation of the role of NSPCs in bone regeneration.


  • Open Access

    Newcastle Disease Virus Displaying an Ectodomain of Middle East Respiratory Syndrome Coronavirus Spike Protein Elicited Robust Humoral and Cellular Immunity in Mice

    by Jaturawitt Prasopsiri, Kanjana Srisutthisamphan, Benjamas Liwnaree, Juggragarn Jengarn, Jarin Kramyu, Payuda Hansoongnern, Papon Muangsanit, Nathiphat Tanwattana, Challika Kaewborisuth, Suttipun Sungsuwan, et al.

    Background: Middle East Respiratory Syndrome Coronavirus (MERS-CoV) causes severe respiratory illness in humans and currently lacks an approved vaccine. The Newcastle disease virus (NDV) vector is a well-established, safe, and effective platform for vaccine development. With recent advancements in stabilizing coronavirus spike proteins to enhance their antigenicity, this study aimed to determine whether modifications to the MERS-CoV spike protein could improve its presentation on NDV particles, allowing the resulting virus to be used as an inactivated vaccine. Methods: We codon-optimized the gene encoding the ectodomain of the MERS-CoV spike protein and incorporated modifications at the S1/S2 and S2’ cleavage sites, along with a proline substitution at residues V1060-L1061. This modified spike gene was inserted into the NDV genome to create the NDV-SMERS virus. After purification and inactivation, the vaccine’s immunogenicity was assessed in mice. Results: Mice immunized with the inactivated NDV-SMERS vaccine developed robust anti-spike IgGs, neutralizing antibodies, and cellular immune responses. The study demonstrated that modifications to the MERS-CoV spike protein were essential for its effective presentation on NDV particles. Additionally, the spike gene insert remained stable through five egg passages, confirming the vector’s stability. Conclusions: Engineering the MERS-CoV spike protein is crucial for its successful display on NDV particles. The strong immune responses elicited by the NDV-SMERS vaccine in mice highlight that NDV is a promising, safe, and effective platform for MERS-CoV vaccination.

  • Open Access

    Harnessing endothelial cells and vascularization strategies for nerve regeneration

    by Papon Muangsanit, Poppy Smith

    An abstract is unavailable. This article is available as a PDF only.


  • Open Access

    Rapidly formed stable and aligned dense collagen gels seeded with Schwann cells support peripheral nerve regeneration

    by Papon Muangsanit, Adam Day, Savvas Dimiou, Altay Frederick Ataç, Céline Kayal, Hyeree Park, Showan N Nazhat, James Benjamin Phillips

    Objective. Gel aspiration-ejection (GAE) has recently been developed for the rapid production of dense, anisotropic collagen gel scaffolds with adjustable collagen fibrillar densities. In this study, a GAE system was applied to produce aligned Schwann cells within a type-1 collagen matrix to generate GAE-engineered neural tissues (GAE-EngNT) for potential nerve tissue engineering applications. Approach. The stability and mechanical properties of the constructs were investigated along with the viability, morphology and distribution of Schwann cells. Having established the methodology to construct stable robust Schwann cell-loaded engineered neural tissues using GAE (GAE-EngNTs), the potential of these constructs in supporting and guiding neuronal regeneration, was assessed both in vitro and in vivo. Main results. Dynamic mechanical analysis strain and frequency sweeps revealed that the GAE-EngNT produced via cannula gauge number 16 G (∼1.2 mm diameter) exhibited similar linear viscoelastic behaviors to rat sciatic nerves. The viability and alignment of seeded Schwann cells in GAE-EngNT were maintained over time post GAE, supporting and guiding neuronal growth in vitro with an optimal cell density of 2.0 × 106 cells ml−1. An in vivo test of the GAE-EngNTs implanted within silicone conduits to bridge a 10 mm gap in rat sciatic nerves for 4 weeks revealed that the constructs significantly promoted axonal regeneration and vascularization across the gap, as compared with the empty conduits although less effective regeneration compared with the autograft groups. Significance. Therefore, this is a promising approach for generating anisotropic and robust engineered tissue which can be used with Schwann cells for peripheral nerve repair.


  • Open Access

    Engineered Aligned Endothelial Cell Structures in Tethered Collagen Hydrogels Promote Peripheral Nerve Regeneration

    by Papon Muangsanit, Victoria Roberton, Eleni Costa, James Phillips

    Vascularisation is important in nerve tissue engineering to provide blood supply and nutrients for long-term survival of implanted cells. Furthermore, blood vessels in regenerating nerves have been shown to serve as tracks for Schwann cells to migrate along and thus form Bands of Büngner which promote axonal regeneration. In this study, we have developed tissue‑engineered constructs containing aligned endothelial cells, or co-cultures of both endothelial cells and Schwann cells to test whether these structures could promote regeneration across peripheral nerve gaps. Type I rat tail collagen gels containing HUVECs (Human Umbilical Vein Endothelial Cells, 4×106 cells/ml) were cast in perforated tethering silicone tubes to facilitate cellular self-alignment and tube formation for 4 days of culture. For co-culture constructs, optimal tube formation and cellular alignment was achieved with a ratio of 4:0.5×106 cells/ml (HUVECs:Schwann cells). An in vivo test of the engineered constructs to bridge a 10 mm gap in rat sciatic nerves for 4 weeks revealed that constructs containing only HUVECs significantly promoted axonal regeneration and vascularisation across the gap, as compared to conventional aligned Schwann cell constructs and those containing co-cultured HUVECs and Schwann cells. Our results suggest that tissue-engineered constructs containing aligned endothelial cells within collagen matrix could be good candidates to treat peripheral nerve injury.